| Abstract | Olopatadine 0.1% (Patanol) and olopatadine 0.2% (Pataday) ophthalmic solutions are topical ocular anti-allergic agents with antihistaminic and mast cell stabilizing properties. The efficacy of two doses of olopatadine 0.1% was compared to one dose of olopatadine 0.2% in the prevention of ocular itching associated with allergic conjunctivitis over 24 hours. This double-masked conjunctival allergen challenge (CAC) study found no significant difference in the mean itching scores between two drops of olopatadine 0.1% and one drop of olopatadine 0.2%. Both showed significant activity at the 24-hour time point and were statistically superior to placebo. No adverse events occurred while on drug therapy. |
| Authors | Mark B Abelson, Dennis L Spangler, Arthur B Epstein, Francis S Mah, H Jerome Crampton
(Affiliation: Harvard Medical School, Schepens Eye Research Institute, Department of Ophthalmology, Boston, Massachusetts, USA.)
|
| Journal | Current eye research
(Curr Eye Res)
Vol. 32
Issue 12
Pg. 1017-22
(Dec 2007)
ISSN: 0271-3683 England |
| PMID | 18085465
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Allergens
- Dibenzoxepins
- Histamine H1 Antagonists, Non-Sedating
- Ophthalmic Solutions
- olopatadine
|
| Topics |
- Adult
- Allergens
(adverse effects)
- Conjunctiva
(drug effects)
- Conjunctivitis, Allergic
(chemically induced, drug therapy)
- Dibenzoxepins
(administration & dosage)
- Double-Blind Method
- Female
- Histamine H1 Antagonists, Non-Sedating
(administration & dosage)
- Humans
- Male
- Ophthalmic Solutions
(administration & dosage)
- Pruritus
(drug therapy)
- Skin Tests
- Treatment Outcome
|
